- Home
- POLA vs BGLC Comparison
POLA vs BGLC Comparison
Compare POLA & BGLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- BGLC
- Stock Information
- Founded
- POLA 1979
- BGLC 2017
- Country
- POLA United States
- BGLC Malaysia
- Employees
- POLA N/A
- BGLC N/A
- Industry
- POLA Industrial Machinery/Components
- BGLC Medical Specialities
- Sector
- POLA Miscellaneous
- BGLC Health Care
- Exchange
- POLA Nasdaq
- BGLC Nasdaq
- Market Cap
- POLA N/A
- BGLC 7.6M
- IPO Year
- POLA 2016
- BGLC N/A
- Fundamental
- Price
- POLA $0.45
- BGLC $0.38
- Analyst Decision
- POLA
- BGLC
- Analyst Count
- POLA 0
- BGLC 0
- Target Price
- POLA N/A
- BGLC N/A
- AVG Volume (30 Days)
- POLA 454.1K
- BGLC 116.1K
- Earning Date
- POLA 11-12-2024
- BGLC 11-20-2024
- Dividend Yield
- POLA N/A
- BGLC N/A
- EPS Growth
- POLA N/A
- BGLC N/A
- EPS
- POLA N/A
- BGLC N/A
- Revenue
- POLA $11,950,000.00
- BGLC $9,183,168.00
- Revenue This Year
- POLA $6.72
- BGLC N/A
- Revenue Next Year
- POLA N/A
- BGLC N/A
- P/E Ratio
- POLA N/A
- BGLC N/A
- Revenue Growth
- POLA N/A
- BGLC N/A
- 52 Week Low
- POLA $0.32
- BGLC $0.31
- 52 Week High
- POLA $0.98
- BGLC $3.39
- Technical
- Relative Strength Index (RSI)
- POLA 49.24
- BGLC 41.00
- Support Level
- POLA $0.44
- BGLC $0.38
- Resistance Level
- POLA $0.54
- BGLC $0.49
- Average True Range (ATR)
- POLA 0.07
- BGLC 0.02
- MACD
- POLA -0.01
- BGLC -0.00
- Stochastic Oscillator
- POLA 20.00
- BGLC 32.66
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.